Get started
Author

S.A. Mathranda

Observed names: S. Mathranda, Sandhya Appachu Mathranda
OpenAlex ID: A5115044827
MicroRNAs as Therapeutic and Prognostic Markers for Resistance to Therapy in HER2/neu-Positive Breast Cancers
2026 · M. Kumar D. V. Praveen, S. Mathranda, et al. · Indian Journal of Medical and Paediatric Oncology
729eP Conversion rates to surgery or radiotherapy with neoadjuvant cetuximab-based therapy in locally advanced head and neck squamous cell carcinoma: AI-assisted peripheral immune biomarkers analysis
2025 · T. Bhumi Gangadhara Reddy, V. Munirathnam, et al. · Annals of Oncology
405P Matched primary-residual tumor analysis identifies estrogen and immune pathways as resistance mechanisms to neoadjuvant therapy in ER+/HER2+ breast cancer
2025 · S.N. Ramesh, S.A. Mathranda, et al. · Annals of Oncology
MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours.
2025 · Sandhya Appachu Mathranda, Praveen Kumar, et al. · Journal of Clinical Oncology
PDF
17P To use or not to use adjuvant trastuzumab emtansine in early breast cancer in resource constrained settings: Can residual cancer burden (RCB) help us to stratify risk of residual disease?
2024 · V. Simha, S. Anantharamu, et al. · Annals of Oncology
PDF
34P MicroRNAs as therapeutic and prognostic markers for resistance to therapy in HER2/neu positive breast cancers
2024 · P.K. D V M, S.A. Mathranda, et al. · Annals of Oncology
PDF
583P Patient reported outcomes with use of orally administered aprepitant in highly and moderately emetogenic (HEC and MEC) regimens
2024 · T. Maneesha, V. Simha, et al. · Annals of Oncology
PDF
556P A prospective observational study to compare the antiemetic efficacy of fosnetupitant + palonosetron vs oral aprepitant + palonosetron
2024 · V. Simha, S. Anantharamu, et al. · Annals of Oncology
PDF
Works count: 8
Citation count:
H-index:
I10-index:
Year
Topic
Type